Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Bristol-Myers Squibb
Study ID
NCT03090737
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Specified Dose on Specified Days

Study Details

A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

Key Dates

Start date
Jun 2, 2017
Status verified
Dec 2022
Primary completion
Feb 16, 2021
Completion
Mar 14, 2022

Study Design

Enrollment
129 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab
    Specified Dose on Specified Days

Primary Outcome Measure

The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE) [ Time Frame: From the first dose of study treatment to up to 30 days of the last dose of study treatment (up to 24 months) ]

Locations (5)

FacilityCityStateZIPSite coordinators
Alabama OncologyBirminghamAlabama35205-
Los Angeles Hematology Oncology Medical GroupLos AngelesCalifornia90017-
St Vincent Frontier Cancer CenterBillingsMontana59102-
Broome OncologyJohnson CityNew York13790-
Guthrie Medical Group SayreSayrePennsylvania18840-

Find similar trials in Birmingham, AL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Alabama Oncology· Birmingham, ALLos Angeles Hematology Oncology Medical Group· Los Angeles, CASt Vincent Frontier Cancer Center· Billings, MTBroome Oncology· Johnson City, NYGuthrie Medical Group Sayre· Sayre, PA

Related Studies